Acquista crypto Mercati Spot FuturesGOLD Earn Centro eventi

Altro

PLANO, Texas–(BUSINESS WIRE)–#Biotech–Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived PLANO, Texas–(BUSINESS WIRE)–#Biotech–Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived

Secretome Therapeutics to Present at the 2026 J.P. Morgan Healthcare Conference

Autore: AI Journal

Fonte: AI Journal

2025/12/30 01:31

2 min di lettura

CELL$0.06489-5.40%

Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

PLANO, Texas–(BUSINESS WIRE)–#Biotech–Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California.

Secretome Therapeutics’ presentation is scheduled for Thursday, January 15, 2026, from 9:00 AM to 9:25 AM (PT).

During the presentation, the company will provide an overview of its proprietary nCPC platform and clinical development programs, including updates on its lead asset, STM-01, which is currently being evaluated in two ongoing Phase 1 clinical trials for heart failure.

“We look forward to presenting at the J.P. Morgan Healthcare Conference and sharing our clinical progress and long-term vision with the global healthcare investment community,” said Vinny Jindal, President and CEO of Secretome Therapeutics. “This conference provides a valuable opportunity to highlight the potential of our nCPC-derived therapies to address significant unmet needs in cardiovascular disease.”

Company management will also be available for one-on-one meetings with investors and potential partners throughout the conference.

About Secretome Therapeutics

Secretome Therapeutics is a clinical-stage biotechnology company based in Plano, Texas, developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs). Our lead product, STM-01, is a first-in-class cellular therapy designed to modulate inflammatory and fibrotic pathways and support myocardial function in dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF). Additionally, Secretome Therapeutics is advancing STM-21, a secretome-based therapeutic currently in preclinical development for inflammatory conditions, including skin wounds and diabetes-associated co-morbidities.

Contacts

Vinny Jindal, President and CEO

vjindal@secretometx.com
https://secretometherapeutics.com/

Opportunità di mercato

Valore Cellframe (CELL)

$0.06489

$0.06489$0.06489

-0.06%

USD

Grafico dei prezzi in tempo reale di Cellframe (CELL)

Get 20 USDT in Just 1 Minute

Deposit $100 to unlock $300 in GOLD positions

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.